N-heterocyclic inhibitors of TNF-α expression
US6906067B2 · kind B2 · utility
21Cited by
13References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 26, 2001 |
| Grant date | Jun 14, 2005 |
| Priority date | — |
| Expiry date | Jun 26, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.